Show simple item record

dc.contributor.authorVanden Eynde, Jean Jacques
dc.date.accessioned2020-04-23T22:43:38Z
dc.date.available2020-04-23T22:43:38Z
dc.date.issued2020-04-10
dc.identifier.urihttps://doi.org/10.3390/ph13040065en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12663/1194
dc.description.abstractCOVID-19 (coronavirus disease 2019) is a worldwide outbreak of pneumonia and acute respiratory distress syndrome. It is unambiguously linked to the human–human transmission of a novel coronavirus. Mutagenomic analyses demonstrated that 79.6% of the genome sequences were identical to those found in the coronavirus responsible for the severe acute respiratory syndrome (SARS), which spread in 2002. Hence the classification as 2019-nCoV (n for novel) and the name SARS-CoV-2. Combatting SARS-CoV-2 has emerged as a tremendous challenge, gathering efforts from academia, pharmaceutical companies, hospitals, international organizations, as well as governments and philanthropic associations (e.g., The Council on Foundations). In this Opinion, we give a brief overview of some current and future clinical trials, as they can be found in the U.S. National Library of Medicine of the National Institutes of Health (Bethesda, MD, USA).en_US
dc.languageEnglishen_US
dc.subjectCOVID-19en_US
dc.subjectCoronavirusen_US
dc.subjectInfectious Diseasesen_US
dc.subjectChloroquineen_US
dc.subjectHydroxychloroquineen_US
dc.subjectLopinaviren_US
dc.subjectRitonaviren_US
dc.subjectSARS-CoV-2en_US
dc.titleCOVID-19: A Brief Overview of the Discovery Clinical Trialen_US
eihealth.countryOthersen_US
eihealth.categoryCandidate therapeutics RDen_US
eihealth.typeResearch protocol informationen_US
eihealth.maincategorySave Lives / Salvar Vidasen_US
dc.relation.ispartofjournalPharmaceuticalsen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record